Όλο το DSpace

Πλοήγηση ανά Θέμα "Rivaroxaban"

Αποτελέσματα 1-15 από 15

    • Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial 

      Ntaios G., Pearce L.A., Meseguer E., Endres M., Amarenco P., Ozturk S., Lang W., Bornstein N.M., Molina C.A., Pagola J., Mundl H., Berkowitz S.D., Liu Y.Y., Sen S., Connolly S.J., Hart R.G. (2019)
      Background and Purpose- Aortic arch atherosclerosis (AAA) is a possible source of embolism in patients with embolic stroke of undetermined source. Previous studies reported high rates of embolic events in patients with ...

    • Atrial cardiopathy and nonstenosing large artery plaque in patients with embolic stroke of undetermined source 

      Kamel H., Pearce L.A., Ntaios G., Gladstone D.J., Perera K., Roine R.O., Meseguer E., Shoamanesh A., Berkowitz S.D., Mundl H., Sharma M., Connolly S.J., Hart R.G., Healey J.S. (2020)
      Background and Purpose—Atrial cardiopathy and atherosclerotic plaque are two potential mechanisms underlying embolic strokes of undetermined source (ESUS). The relationship between these two mechanisms among ESUS patients ...

    • Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial 

      Kasner S.E., Lavados P., Sharma M., Wang Y., Wang Y., Dávalos A., Shamalov N., Cunha L., Lindgren A., Mikulik R., Arauz A., Lang W., Czlonkowska A., Eckstein J., Gagliardi R., Amarenco P., Ameriso S.F., Tatlisumak T., Veltkamp R., Hankey G.J., Toni D.S., Bereczki D., Uchiyama S., Ntaios G., Yoon B.-W., Brouns R., DeVries Basson M.M., Endres M., Muir K., Bornstein N., Ozturk S., O'Donnell M., Mundl H., Pater C., Weitz J., Peacock W.F., Swaminathan B., Kirsch B., Berkowitz S.D., Peters G., Pare G., Themeles E., Shoamanesh A., Connolly S.J., Hart R.G., NAVIGATE ESUS Steering Committee and Investigators (2018)
      Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing ...

    • Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece 

      Gourzoulidis G., Kourlaba G., Kakisis J., Matsagkas M., Giannakoulas G., Gourgoulianis K.I., Vassilakopoulos T., Maniadakis N. (2017)
      Background and Objective: Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a major healthcare concern that results in substantial morbidity and mortality with great economic ...

    • Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study 

      Paciaroni M., Agnelli G., Falocci N., Tsivgoulis G., Vadikolias K., Liantinioti C., Chondrogianni M., Bovi P., Carletti M., Cappellari M., Zedde M., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Silvestrelli G., Lanari A., Ciccone A., Putaala J., Tomppo L., Tatlisumak T., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D'Amore C., Becattini C., Mosconi M.G., Cimini L.A., Soloperto R., Masotti L., Vannucchi V., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Sohn S.-I., Marcheselli S., Mumoli N., De Lodovici M.L., Bono G., Furie K.L., Tadi P., Yaghi S., Toni D., Letteri F., Tassinari T., Kargiotis O., Lotti E.M., Flomin Y., Mancuso M., Maccarrone M., Giannini N., Bandini F., Pezzini A., Poli L., Padovani A., Scoditti U., Denti L., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Gourbali V., Orlandi G., Giuntini M., Chiti A., Giorli E., Gialdini G., Corea F., Ageno W., Bellesini M., Colombo G., Monaco S., Baronello M.M., Karapanayiotides T., Caso V. (2017)
      Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated ...

    • Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies 

      Archontakis-Barakakis P., Li W., Kalaitzoglou D., Tzelves L., Manolopoulos A., Giannopoulos S., Giamouzis G., Giannakoulas G., Batsidis A., Palaiodimos L., Ntaios G., Lip G.Y.H., Kokkinidis D.G. (2022)
      Aims: Observational studies have investigated the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial fibrillation. We performed a systematic review ...

    • Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis 

      Ntaios G., Swaminathan B., Berkowitz S.D., Gagliardi R.J., Lang W., Siegler J.E., Lavados P., Mundl H., Bornstein N., Meseguer E., Amarenco P., Cucchiara B., Camps-Renom P., Makaritsis K., Korompoki E., Papavasileiou V., Marti-Fabregas J., Milionis H., Vemmos K., Connolly S.J., Hart R.G. (2019)
      Background and Purpose - The sources of emboli in patients with embolic stroke of undetermined source (ESUS) are multiple and may not respond uniformly to anticoagulation. In this exploratory subgroup analysis of patients ...

    • Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis 

      Karathanos C., Nana P., Spanos K., Kouvelos G., Brotis A., Matsagas M., Giannoukas A. (2021)
      Objective: Direct oral anticoagulants (DOACs) have been recommended for the treatment of deep vein thrombosis (DVT). However, the benefits are uncertain for the prevention of post-thrombotic syndrome (PTS). We performed a ...

    • Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy 

      Ameriso S.F., Amarenco P., Pearce L.A., Perera K.S., Ntaios G., Lang W., Bereczki D., Uchiyama S., Kasner S.E., Yoon B.-W., Lavados P., Firstenfeld A., Mikulik R., Povedano G.P., Ferrari J., Mundl H., Berkowitz S.D., Connolly S.J., Hart R.G. (2020)
      Background: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of ...

    • Microbleeds and the Effect of Anticoagulation in Patients with Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial 

      Shoamanesh A., Hart R.G., Connolly S.J., Kasner S.E., Smith E.E., Martí-Fàbregas J., Liu Y.Y., Uchiyama S., Mikulik R., Veltkamp R., O'Donnell M.J., Ntaios G., Muir K.W., Field T.S., Santo G.C., Olavarria V., Mundl H., Lutsep H., Berkowitz S.D., Sharma M. (2021)
      Importance: The reported associations of cerebral microbleeds with recurrent stroke and intracerebral hemorrhage have raised concerns regarding antithrombotic treatment in patients with a history of stroke and microbleeds ...

    • Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial 

      Ntaios G., Pearce L.A., Veltkamp R., Sharma M., Kasner S.E., Korompoki E., Milionis H., Mundl H., Berkowitz S.D., Connolly S.J., Hart R.G. (2020)
      Background and Purpose - Emboli in embolic stroke of undetermined source (ESUS) may originate from various potential embolic sources (PES), some of which may respond better to anticoagulation, whereas others to antiplatelets. ...

    • Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial 

      Hart R.G., Veltkamp R.C., Sheridan P., Sharma M., Kasner S.E., Bangdiwala S.I., Ntaios G., Shoamanesh A., Ameriso S.F., Toni D., Czlonkowska A., Lindgren A., Hankey G.J., Perera K.S., Shuaib A., Coutts S.B., Gagliardi R.J., Berkowitz S.D., Mundl H., Peters G., Connolly S.J., NAVIGATE ESUS Investigators (2019)
      Background: Embolic stroke of undetermined source (ESUS) identifies patients with cryptogenic ischemic stroke presumed due to embolism from several unidentified sources. Among patients with recent ESUS, we sought to determine ...

    • Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis 

      Ntaios G., Papavasileiou V., Makaritsis K., Vemmos K., Michel P., Lip G.Y.H. (2017)
      Background and Purpose - Evidence from the real-world setting complements evidence coming from randomized controlled trials. We aimed to summarize all available evidence from high-quality real-world observational studies ...

    • Recurrent Stroke with Rivaroxaban Compared with Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial 

      Healey J.S., Gladstone D.J., Swaminathan B., Eckstein J., Mundl H., Epstein A.E., Haeusler K.G., Mikulik R., Kasner S.E., Toni D., Arauz A., Ntaios G., Hankey G.J., Perera K., Pagola J., Shuaib A., Lutsep H., Yang X., Uchiyama S., Endres M., Coutts S.B., Karliński M., Czlonkowska A., Molina C.A., Santo G., Berkowitz S.D., Hart R.G., Connolly S.J. (2019)
      Importance: The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it ...

    • Rivaroxaban for stroke prevention after embolic stroke of undetermined source 

      Hart R.G., Sharma M., Mundl H., Kasner S.E., Bangdiwala S.I., Berkowitz S.D., Swaminathan B., Lavados P., Wang Y., Wang Y., Davalos A., Shamalov N., Mikulik R., Cunha L., Lindgren A., Arauz A., Lang W., Czlonkowska A., Eckstein J., Gagliardi R.J., Amarenco P., Ameriso S.F., Tatlisumak T., Veltkamp R., Hankey G.J., Toni D., Bereczki D., Uchiyama S., Ntaios G., Yoon B.-W., Brouns R., Endres M., Muir K.W., Bornstein N., Ozturk S., O'Donnell M.J., De Vries Basson M.M., Pare G., Pater C., Kirsch B., Sheridan P., Peters G., Weitz J.I., Peacock W.F., Shoamanesh A., Benavente O.R., Joyner C., Themeles E., Connolly S.J., for the NAVIGATE ESUS Investigators (2018)
      BACKGROUND Embolic strokes of undetermined source represent 20% of ischemic strokes and are associated with a high rate of recurrence. Anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, may result in a ...